Clinical trials for Anal cancer

91 currently recruiting clinical trials
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Ileum cancer Neuroendocrine tumor None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Anal cancer #NCT06207981 #2023-505972-32-00
Locally Advanced
Radiotherapy Radiotherapy
47 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 2 / Phase 3 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06943755 #2025-521043-20-00
Neuroendocrine tumor Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Exélixis
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Neuroendocrine carcinoma MSI/dMMR None Systemic Treatment-Naive
Immunotherapy Radiotherapy
6 recruiting sites
UNICANCER
Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer #NCT07061080 #2024-514327-42-00
Stomach Oesogastric junction Esophagus Neuroendocrine carcinoma Locally Advanced Metastatic 1 Chemotherapy
1 recruiting site
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04954820
Neuroendocrine tumor 1 SSTR Positive
Systemic Treatment-Naive Systemic Treatment-Naive
26 recruiting sites
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04268121 #2024-515603-19-01
Neuroendocrine carcinoma Localized None Systemic Treatment-Naive
10 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Locally Advanced Metastatic Metastatic Castration-resistant EGFR FGFR MET 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron